Vaccines to Prevent High-Grade Glioma

Video

This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

In this video, Hideho Okada, MD, PhD, of the University of California, San Francisco, discusses current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

Okada gave a presentation on this topic at the 2017 American Association for Cancer Researcher (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Historical standards for H3 K27M-mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD.
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.